The Preventative Effects of Recombinant Thrombomodulin on Transplantation-Associated Coagulopathy after Allogeneic Hematopoietic Stem Cell Transplantation

نویسندگان

  • Shosaku Nomura
  • Kazuyoshi Ishii
  • Yoshinobu Maeda
  • Yuta Katayama
  • Hideo Yagi
  • Naohito Fujishima
  • Shuichi Ota
  • Masanori Seki
  • Masaya Okada
  • Takayuki Ikezoe
  • Kunio Hayashi
  • Shinya Fujita
  • Atsushi Satake
  • Tomoki Ito
  • Taiichi Kyo
  • Yoji Ishida
  • Shigeru Chiba
  • Kenichi Sawada
چکیده

Hematopoietic Stem Cell Transplantation (HSCT) involves specific serious transplant-related complications [1,2], and recovery from these complications is vital for achieving a successful HSCT outcome. Therefore, taking steps to mitigate coagulationand Graft-Versus Host Disease (GVHD)-related complications following HSCT is very important. Several interactions between coagulation-related blood components and the fibrinolytic systems are involved in the progression of vascular angiopathy. Notably, plasminogen activator inhibitor (PAI)-1 plays an important role in the pathophysiology of many vascular abnormalities [3]. Recombinant thrombomodulin (rTM) is composed of the active extracellular domain of TM. Like membranebound TM, rTM binds to thrombin to inactive coagulation. The thrombin–rTM complex activates protein C to produce active protein C (APC), which in the presence of protein S inactivates factors VIIIa and Va, thereby inhibiting further thrombin formation [4]. Therefore, rTM might be useful for transplantation-associated coagulopathy (TAC) after HSCT. Indeed, there are some reports of the efficacies of therapies for TAC, such as veno-occlusive disease (VOD) and thrombotic microangiopathy (TMA) [5,6]. However, the preventive effects of rTM for TAC or TAC-related biomarkers following HSCT are poorly understood. Here, we investigated the preventive effects of rTM for TAC and TAC-related biomarker levels after HSCT. To our knowledge, this report of a multi-institutional joint study is the first to document the potential ability of rTM to prevent TAC after HSCT. The study cohort included 271 patients who underwent SCT between June 2011 and February 2014 at one of 24 institutions in Japan. All patients received allogeneic SCT (Table 1). The 161 male and 110 female allogeneic SCT patients ranged in age from 7 to 71 years (median: 45 years). Patient diagnoses consisted of 102 acute myeloid leukemia cases, 63 acute lymphoblastic leukemia cases, 38 myelodysplastic syndrome cases and 68 other diagnoses. Conditioning was applied as follows: total body irradiation for 175 patients and non-total body irradiation for 96 patients. The donor sources for transplantation were 139 bone marrow cells, 57 peripheral blood stem cells and 75 cord blood cells (Table 1). Written informed consent was obtained from all patients who were registered by faxing documents to Kansai Medical University prior to SCT. The rTM, consisting of daily doses of 380 units/kg (Asahi Kasei Pharma, Tokyo, Japan), was administered as a preventive therapy for TAC. This protocol was Abstract

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Assessment of Cyclosporine Serum Concentrations on the Incidence of Acute Graft versus Host Disease Post Hematopoietic Stem Cell Transplantation

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment option for hematological disorders. Cyclosporine (CsA) is one of the major immunosuppressive agents for the prophylaxis against graft versus host disease (GvHD). In this retrospective study, we evaluated the effects of CsA serum levels on the incidence of acute GvHD and transplant outcomes. 103 adult patients rece...

متن کامل

A 16 Month Survey of Cyclosporine Utilization Evaluation in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Objectives: Graft versus host disease (GVHD) is a life threatening reaction in the stem cell transplantation process. Nowadays Cyclosporine is the most commonly utilized agent for GVHD prophylaxis and it has a major role in successful transplantation. Cyclosporine has been applied for many years in this field but it could be stated that currently no general consensus is available for its optima...

متن کامل

A 16 Month Survey of Cyclosporine Utilization Evaluation in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Objectives: Graft versus host disease (GVHD) is a life threatening reaction in the stem cell transplantation process. Nowadays Cyclosporine is the most commonly utilized agent for GVHD prophylaxis and it has a major role in successful transplantation. Cyclosporine has been applied for many years in this field but it could be stated that currently no general consensus is available for its optima...

متن کامل

Hematopoietic Stem Cell Transplantation for Thalassemia

Thalassemia is an autosomal recessive disorder associated with defective synthesis of the α- or β-chain of hemoglobin. For β-thalassemia major patients, therapeutic options are either monthly red cell transfusions and chelation therapy or allogeneic stem cell transplant. Stem cell transplant is the only curative approach and success is inversely correlated with the degree of iron overload and h...

متن کامل

Feasibility of high-dose iodine-131-metaiodobenzylguanidine therapy for high-risk neuroblastoma preceding myeloablative chemotherapy and hematopoietic stem cell transplantation: a study protocol

Objective(s): High-risk neuroblastoma is a childhood cancer with poorprognosis despite modern multimodality therapy. Internal radiotherapy using131I-metaiodobenzylguanidine (MIBG) is effective for treating the disease even if it isresistant to chemotherapy. The aim of this study is to evaluate the safety and efficacyof 131I-MIBG radiotherapy combined with myeloablative high-dose chemotherapyand...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2014